Protein structure
Three-dimensional arrangement of atoms in an amino acid-chain molecule
Follow Protein structure on Notably News to receive short updates to your email — rarely!
We include updates on HPV vaccine, Ubiquitin, X-ray crystallography, Gardasil, Beta sheet, Peptide bond, Alpha helix, Circular dichroism, Dihedral angle, Folding@home, Cryogenic electron microscopy, His-tag, Malaria vaccine, Disulfide, Post-translational modification, Zinc finger ... and more.
| April 2 2025 |
DreamLab
DreamLab was discontinued after approximately a decade of operation.
|
| 2024 |
Rosetta@home
The Rosetta computer program was cited in the Scientific Background to the Nobel Prize in Chemistry.
|
| 2024 |
Noora
Independent research revealed that the Noora vaccine has poor immunogenicity and neutralization efficacy, making it unlikely to be useful against later SARS-CoV-2 variants.
|
| March 2024 |
Noora
An independent research team from Tehran University of Medical Sciences and Avicenna Research Institute published a report in the Iranian Journal of Immunology, concluding that Noora vaccine lacks expected efficacy and does not provide protection against SARS-CoV-2 Delta or later variants.
|
| March 2 2024 |
Noora
The Journal of Medical Virology officially retracted the Noora vaccine research paper due to data inconsistencies, undisclosed conflicts of interest, and failure of the authors to adequately respond to criticism.
|
| November 23 2023 |
Noora
The authors of the Noora vaccine study missed the final deadline for revision of their research paper, after three rounds of peer review.
|
| September 2023 |
Skycovione
SK Bioscience withdrew the application for marketing authorization in the European Union.
|
| May 2023 |
Noora
The clinical trial for Noora vaccine underwent critical scrutiny in the Journal of Medical Virology.
|
| 2022 |
Rosetta@home
Antiviral candidates forecasted to begin clinical trials, with funding from the Bill & Melinda Gates Foundation for preclinical and early clinical trials.
|
| 2022 |
Noora
By early 2022, the Noora vaccine reached a production milestone of 3 million doses produced monthly.
|
| 2022 |
S-268019
A non-human primate study concluded S-268019-b demonstrated efficacy in a SARS-CoV-2 challenge experiment, while showing reduced neutralizing antibodies against the Omicron variant.
|
| November 2022 |
Skycovione
Production of Skycovione was indefinitely suspended due to low demand. Out of 10 million doses purchased by the South Korean government, only 600,000 were released to hospitals, with just 3,787 shots administered.
|
| September 2022 |
Noora
Vaccine preparation and preclinical tests in mice, rabbits, and monkeys were reported in the journal Molecular Immunology.
|
| August 27 2022 |
Noora
First clinical trial results published in the Journal of Medical Virology, led by Salimian and Amani, and supervised by Hassan Abolghasemi and Gholamhossein Alishiri. The report claimed the vaccine is effective, safe, and capable of providing immunity.
|
| June 29 2022 |
Skycovione
Skycovione received approval for use in South Korea, with a note that an additional safety review was needed due to the small trial participant group.
|
| June 27 2022 |
Skycovione
The Korean Ministry of Food and Drug Safety completed its review of Skycovione, declaring the data sufficient for approval.
|
| April 2022 |
Skycovione
Phase III clinical trial results confirmed Skycovione to be safe and effective, showing approximately three times more antibodies than the Oxford–AstraZeneca COVID-19 vaccine.
|
| March 2022 |
Noora
Hassan Abolqasemi announced the completion of Phase III clinical trial with 10,000 participants. The Iranian Ministry of Health subsequently granted emergency use permit for the vaccine.
|
| January 2022 |
Corbevax
Developers highlighted lack of G7 funding for the project. 70 million doses of Corbevax had been administered to adolescents in India. The vaccine was also approved by the Botswana Medicines Regulator Authority.
|
| 2021 |
SCB-2019
Vaccine production of SCB-2019 is expected to begin.
|
| 2021 |
SCB-2019
Began vaccine production after receiving advanced purchase orders from GAVI for 400 million doses.
|
| 2021 | Bertolini et al. published research presenting evidence that homomer formation may be driven by interactions between nascent polypeptide chains during translation by adjacent ribosomes. |
| December 2021 |
Cryogenic electron microscopy
Researchers at the Dubochet Center For Imaging rapidly identified and defined the structure of the SARS-CoV-2 Omicron variant, providing crucial insights into its mutations and potential therapeutic approaches.
|
| December 2021 |
S-268019
A phase 3 clinical trial began in Vietnam, planning to involve 54,915 participants.
|
| December 28 2021 |
Corbevax
India approved the Corbevax vaccine for emergency use after Biological E announced positive results, claiming over 90% effectiveness against the original COVID-19 variant.
|
| December 23 2021 |
Noora
Phase III clinical trials of Noora vaccine initiated, involving a large-scale study with 10,000 participants over 18 years old.
|
| November 2021 |
Cryogenic electron microscopy
The Dubochet Center For Imaging (DCI) was opened by the Federal Institute of Technology, University of Lausanne, and University of Geneva to apply and develop cryo-EM technology.
|
| October 2021 |
SCB-2019
Clover planned to submit Phase III results for approval to the World Health Organization, European Medicines Agency, and China's NMPA in the fourth quarter.
|
| October 10 2021 |
Noora
Phase II clinical trials of Noora vaccine commenced, with 300 total participants. The trial included 240 vaccine recipients and 60 placebo recipients, focusing on participants aged 18-40 years.
|
| September 2021 |
SCB-2019
Results published in The Journal of Infectious Diseases demonstrated that SCB-2019 induced antibody responses lasting up to 184 days in its Phase I trial, and successfully produced neutralizing antibodies against Alpha, Beta, and Gamma COVID-19 variants.
|
| September 2021 |
SCB-2019
Phase II/III trials revealed SCB-2019 vaccine candidate showed 79% efficacy against the delta variant of COVID-19.
|
| September 2021 |
SCB-2019
SCB-2019 announced Phase III results showing 67.2% overall efficacy against COVID-19, 83.7% efficacy against moderate-to-severe disease, and 100% efficacy against hospitalisation and severe cases.
|
| September 2021 |
SCB-2019
Announced Phase III trial results showing 67% overall efficacy against COVID-19, 79% efficacy against Delta variant, 84% effectiveness against moderate cases, and 100% effectiveness against hospitalization.
|
| August 2021 |
Noora
Phase I clinical trial of Noora vaccine completed, involving 70 volunteers.
|
| August 2021 |
Noora
Noora vaccine announced to have successfully passed the first phase of its clinical trial.
|
| August 2021 |
West China Hospital COVID-19 vaccine
WestVac Biopharma initiated phase I/II clinical trials with 600 participants targeting children and adolescents aged 6-17.
|
| August 2021 |
SCB-2019
Phase II clinical trials of SCB-2019 vaccine planned to launch in China with 800 participants, focusing on assessing immunogenicity and safety.
|
| July 2021 |
202-CoV
The Coalition for Epidemic Preparedness Innovations (CEPI) partnered with Shanghai Zerun Biotechnology and Walvax Biotech to develop COVID-19 vaccine candidates targeting both original SARS-CoV-2 strain and newer variants. CEPI provided up to $25.1 million USD in funding, though they subsequently ceased further financial support.
|
| July 2021 |
SCB-2019
Enrollment in the Phase II/III trials was completed, with a total of 29,000 participants across multiple continents: 45% in Asia, 45% in Latin America, and the remaining participants in Europe and Africa.
|
| July 2021 |
SCB-2019
Completed enrollment of 29,000 participants in Phase II/III clinical trials for the SCB-2019 COVID-19 vaccine.
|
| June 2021 |
Rosetta@home
Icosavax began a Phase I/II clinical trial for the IVX-411 vaccine, developed with contributions from Rosetta@home volunteers.
|
| June 2021 |
West China Hospital COVID-19 vaccine
WestVac Biopharma launched phase III clinical trials involving 40,000 participants across Indonesia, Kenya, and the Philippines.
|
| June 27 2021 |
Noora
Noora vaccine was officially launched with its Phase I clinical trial, officiated by IRGC Commander-in-Chief Major General Hossein Salami and Health Minister Saeed Namaki. Hossein Samadinia, head of the Baqiyatallah Hospital, received the first dose during the inaugural event.
|
| June 25 2021 |
Noora
Phase I clinical trials of Noora vaccine began, involving 70 participants aged 18-50 years. The trial included 30 participants receiving 80 μg vaccine, 30 receiving 120 μg vaccine, and 10 receiving placebo.
|
| June 3 2021 |
Corbevax
India's Ministry of Health and Family Welfare pre-ordered 300 million doses of the Corbevax vaccine.
|
| May 2021 |
Rosetta@home
NL-201, a cancer drug candidate first created at the Institute of Protein Design, began a Phase 1 Human clinical trial with support from Neoleukin Therapeutics, with Rosetta@home contributing to its development through 'forward folding' experiments.
|
| May 5 2021 |
Rosetta@home
Phase 1 human clinical trial of NL-201 begins, with plans to enroll up to 120 participants in the United States and Australia.
|
|
We are only showing the most recent entries for this topic. |
|
This contents of the box above is based on material from the Wikipedia articles Corbevax, Noora (vaccine), Rosetta@home, DreamLab, Skycovione, Protein structure, Cryogenic electron microscopy, West China Hospital COVID-19 vaccine, SCB-2019, S-268019, Disulfide, 202-CoV & Statistical potential, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.